Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 395 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Please find attached intimation under Regulation 30 of SEBI (LODR) Regualtions, 2015
Regulatory Filings Classification · 85% confidence The document is a stock exchange filing under SEBI Listing Regulations (Regulation 30, 33, 51, etc.) notifying the Outcome of Board Meeting, including approval of audited financial results, reappointments of directors, cost auditors, noting resignations, and investment approvals. It does not itself contain the full annual or interim report, but is a regulatory disclosure to BSE/NSE. This falls under general regulatory filings, so it is classified as RNS (Regulatory Filings).
2026-05-19 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 98% confidence The document is a formal filing to stock exchanges announcing the allotment of 80,872 new equity shares under the company’s Employee Stock Option Plan, including updated paid-up capital figures and regulatory disclosures under SEBI share-based benefits regulations. This is a corporate announcement of a new share issue/capital change, matching the “Share Issue/Capital Change” category.
2026-05-19 English
Please find attached Audited Financail Results for the quarter and year ended March 31, 2026
Interim / Quarterly Report Classification · 84% confidence The document is a board meeting outcome submitted under SEBI Listing Regulations (Reg. 30, 33, 52), primarily to announce and attach the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, along with the auditor’s report. It also includes corporate actions (director re-appointment, resignation, cost auditor re-appointment, security realignment, additional subsidiary investment), but its core purpose is the quarterly financial results filing with detailed audit opinion. This aligns with a comprehensive Interim/Quarterly Report rather than a simple earnings release or just a management change notice. Therefore, it classifies as an Interim / Quarterly Report. FY 2026
2026-05-19 English
Cessation
Interim / Quarterly Report Classification · 85% confidence The document is a formal board meeting outcome filed under SEBI LODR Regulations, which (1) approves and encloses the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, and (2) includes the full auditor’s report on those results. It is not merely an announcement that a report is attached (RPA) but contains the substantive interim financial statements and audit opinion. Therefore, this corresponds to a comprehensive quarterly/interim financial report (IR). FY 2026
2026-05-19 English
Please find attached the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026
Interim / Quarterly Report Classification · 87% confidence The document is a formal listing-regulation disclosure titled “Outcome of Board Meeting” submitted to stock exchanges under SEBI LODR regulations, approved by the Board of Directors of Mankind Pharma Limited. It primarily presents the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 along with the independent auditor’s report and related financial data. It also covers Board approvals (e.g., NCD realignment, director reappointment/resignation, cost auditors’ appointment, subsidiary investment) but the central feature is the publication of the quarter-end and year-end audited financial statements. It is far more substantive than a brief earnings release and contains actual financial statements and auditor’s opinion. Under the classification definitions, this conforms to an Interim/Quarterly Report (IR) — a comprehensive financial report for a period shorter than a full fiscal year that includes substantive financial data and analysis. FY 2026
2026-05-19 English
Appointment
Regulatory Filings Classification · 90% confidence The document is titled “Outcome of Board Meeting” and is addressed to BSE and NSE under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It reports regulatory compliance items including approval of audited standalone and consolidated financial results, director reappointments, resignation of senior management, appointment of cost auditors, and related certificates. It is a statutory filing to the stock exchanges rather than the full annual report, a US 10-K, or a standalone earnings release. Under the classification scheme, this general regulatory announcement and compliance disclosure falls under Regulatory Filings (RNS).
2026-05-19 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.